What I do

Welcome to Shen Lin's website! I am a research scientist working in a biotech startup called Talee Bio. Talee Bio aims to eradicated cystic fibrosis using gene therapy technology. These gene therapy products are the result of many years of research geared to overcome barriers that have prevented effective treatment of cystic fibrosis.

For more about Talee Bio, please visit the website:


Cystic fibrosis is a devastating genetic disease caused by mutations in a single gene, cystic fibrosis transmembrane conductance regulator (CFTR). CFTR conducts chloride and bicarbonate ions across the epithelial cell membranes. Dysfunction of the gene causes disrupted mucociliary transport, airway bacterial infections, diseases in the gut, diabetes, liver failure and ultimately death. Cystic fibrosis is a progressive disease detectable at birth, and symptoms worsen during growth leading to chronic inflammation, infection and bronchiectasis. The average life expectancy of an adult with cystic fibrosis is now 39.

Cystic fibrosis is primarily an airway disease resulting in progressive respiratory failure. It occurs in 1 out of 1000 individuals in the US, affecting approximately 70,000 people worldwide. There are currently a few approved drug treatments which improve lung function but these target only a small proportion of patients with cystic fibrosis with a common mutation. Most therapies mitigate the symptoms rather than the cause of the disease. My aim at Talee is to develop a viable AAV and lentivirus treatment effectively eliminate the mutated gene.


    About Shen Lin

I am a research scientist located at the University of Iowa, in Iowa City IA. I am working with the founders of Talee Bio on a cure for cystic fibrosis. I am working in conjunction with the board of directors at Talee's headquarters based in Philadelphia PA, under the umbrella venture-led startup organization of Militia Hill Ventures.

For the past decade I have been a neuroscientist studying ways to augment regrowth of damaged axons after spinal cord injury. My research to understand how axons grow by manipulating the neuronal cytoskeleton led me to the use of viral vectors for gene transduction. With the advent of the first FDA approved gene therapy I am planning to harness my knowledge in viral vector production to develop viable viral gene therapies.

I graduated from King's College London in 2008 with a PhD in developmental neurbiology and finished my undergraduate degree in neuroscience in 2004 also at King's.  I have a Masters degree in Quality Assurance and Regulatory Affairs from Temple University in Philadelphia, which I completed in 2017 at the end of my postdoc. I have a thorough academic understanding of the FDA regulatory process and requirements for drug development and quality assurance. I hope to use my knowledge to bridge the gap between bench science and clinical research.

In my spare time I like to travel on long roadtrips and take amature photographs of beautiful things. I also enjoy cooking food and editing my own website.



For an exploration of my photography please visit https://www.flickr.com/people/lostinflickrama/:




  • margin
    Leave Your Comments!
comments powered by Disqus

Affiliated Organizations

Talee Bio Inc


University of Iowa Health

University of Iowa